The Danish enzyme maker reported 9.8% revenue growth in Q2 and raised its long-term organic sales outlook.
Novozymes posted Q2 revenue of €1.12 billion, up 9.8% year-over-year, driven by broad-based organic sales growth of 8%. The company cited a 1.5 percentage point negative impact from exiting certain markets.
Adjusted EBITDA margin reached 37.7%, a 30 basis point improvement from the prior year, though down from 120 basis points in Q2. The company also announced an inaugural €1 billion share buyback plan and raised its FY26 organic sales growth outlook.
Non-GAAP earnings per share stood at €0.52 for the quarter.